Literature DB >> 1424425

Time course of tolerance to apomorphine in parkinsonism.

S T Gancher1, J G Nutt, W R Woodward.   

Abstract

We sought to determine if tolerance developed to the antiparkinsonian effects of apomorphine and, if so, what temporal factors influenced its development. Seven patients with parkinsonism and motor fluctuations received short (6-hour) and long (22- to 31-hour) apomorphine infusions. Tolerance was evaluated by comparison of the responses to test doses of apomorphine that were administered before and after each infusion. The responses to the test doses that followed either infusion were reduced by 35% after the short infusion and by 68% after the long infusion, although plasma apomorphine levels were similar to or higher than levels achieved with preinfusion test doses. The duration of improvement in parkinsonism after discontinuation of the long infusion was briefer than that after the short infusion. We conclude that tolerance to apomorphine occurs in parkinsonism, and the loss of response is greater after longer periods of drug administration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424425     DOI: 10.1038/clpt.1992.178

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 2.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Authors:  C Neef; T van Laar
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 4.  Closing the loop for patients with Parkinson disease: where are we?

Authors:  Hazhir Teymourian; Farshad Tehrani; Katherine Longardner; Kuldeep Mahato; Tatiana Podhajny; Jong-Min Moon; Yugender Goud Kotagiri; Juliane R Sempionatto; Irene Litvan; Joseph Wang
Journal:  Nat Rev Neurol       Date:  2022-06-09       Impact factor: 44.711

Review 5.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 6.  Current status of dopamine agonists in Parkinson's disease management.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Induction of tolerance of dopaminergic responses in man.

Authors:  S Lal; J X Thavundayil; N M K Ng Ying Kin; X Dai; G Schwartz; A Montoya
Journal:  J Neural Transm (Vienna)       Date:  2008-05-28       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.